Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy

Amjad A. Ilyas, Francis A. Mithen, Marinos C. Dalakas, Zi Wei Chen, Stuart D. Cook

Research output: Contribution to journalArticlepeer-review

151 Scopus citations


Using an enzyme-linked immunosorbent assay and a thin-layer chromatography-immunostaining procedure, we detected serum antibodies against acidic glycolipids in 36 of 53 patients with Guillain-Barré syndrome (GBS) and 8 of 16 patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Although we also found anti-acidic glycolipid antibodies in 4 of 13 patients with other neurological diseases; 2 of 10 patients with multiple sclerosis; 8 of 33 patients with inflammatory, infectious, allergic or autoimmune disorders and 3 of 32 healthy subjects, the levels of antibodies in these controls were much lower than in GBS patients. There were several patterns of reactivity of GBS sera including antibodies to LM1 and HexLM1, GM1 or GD1b or both, various other gangliosides, sulfated glycolipids, and as yet unidentified glycolipids. Sera from 30% of GBS patients had antibodies against two or more antigenically distinct acidic glycolipid antigens. Levels of anti-acidic glycolipid antibodies correlated with clinical symptoms in 9 of 11 GBS patients. While the increased incidence of antibodies to acidic glycolipids in patients with GBS (P < 0.001) and CIDP (P < 0.025) compared to controls could be an epiphenomenon, anti-acidic glycolipid antibodies may play a role in nerve injury in some GBS and CIDP patients.

Original languageEnglish (US)
Pages (from-to)111-121
Number of pages11
JournalJournal of the Neurological Sciences
Issue number1
StatePublished - Jan 1992

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology


  • Acidic glycolipids
  • Chronic inflammatory demyelinating polyneuropathy
  • Guillain-Barré syndrome


Dive into the research topics of 'Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

Cite this